Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Melanoma 23Multiple Myeloma 9Colorectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Thyroid Neoplasms 8Glioma 8Neoplasm Metastasis 7Hematologic Neoplasms 6Thyroid Carcinoma, Anaplastic 5Lymphoma 5Thyroid Cancer, Papillary 4Pancreatic Neoplasms 4Neurofibromatosis 1 4Neoplasms 4Lung Neoplasms 3Brain Neoplasms 3Astrocytoma 3Adenocarcinoma, Follicular 3Skin Neoplasms 2Recurrence 2Rectal Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neurofibroma, Plexiform 2Leukemia, Myelomonocytic, Juvenile 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Colonic Neoplasms 2Advanced Solid Tumors 2Uveal Melanoma 1

Interventions

trametinib 1spartalizumab 1pembrolizumab 1lenvatinib 1gallium Ga 68 dotatate 1dabrafenib 1Sorafenib 1Sodium Iodide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, Hurthle cell × trametinib × 1 year × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡